Featured Research

from universities, journals, and other organizations

Lack Of Association Between Autoimmune Antibodies And Improved Outcome In Melanoma Patients

Date:
June 9, 2009
Source:
Journal of the National Cancer Institute
Summary:
Contrary to previous reports, the appearance of autoantibodies is not strongly associated with improved outcome in melanoma patients treated with interferon, according to a new study.

Contrary to previous reports, the appearance of autoantibodies is not strongly associated with improved outcome in melanoma patients treated with interferon, according to a new study.

Related Articles


Results were published in  the June 9 online issue of the Journal of the National Cancer Institute.

Adjuvant treatment of melanoma with interferon-α (IFN) has been shown to increase recurrence-free survival. In this study, Alexander M.M Eggermont, M.D., at Erasmus University MC in the Netherlands, and colleagues, looked at randomized controlled clinical trials in which patients with melanoma received or did not receive intermediate doses of IFN. Using statistical models accounting for guarantee-time bias--which is the additional time that patients with improved outcomes would have to become antibody-positive--they did not find a statistically significant association between autoantibodies after initiation of treatment and the length of time to recurrence.

Serum levels of antibodies were determined using enzyme-linked immunosorbent assays in over 500 patients in the European Organization for Research and Treatment of Cancer (EORTC18952) and Nordic IFN trials. Cox regression models were used to assess the association of seroconversion with recurrence-free survival.

When treated as a time-independent variable, appearance of autoantibodies was associated with improved relapse-free interval in both trials, but correction for guarantee-time bias found that the association was not statistically significant.

"The results of two similar randomized trials reported here do not suggest that the presence or appearance of autoantibodies is a strong prognostic factor in melanoma patients," the authors write. "The findings indicate that the assessment of autoimmune antibodies is not a useful tool in selecting patients who would benefit from treatment with intermediate doses of IFN-a2b."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Marna G. Bouwhuis, Stefan Suciu, Sandra Collette, Steinar Aamdal, Wim H. Kruit, Lars Bastholt, Ulrika Stierner, Franηois Salθs, Poulam Patel, Cornelis J. A. Punt, Micaela Hernberg, Alain Spatz, Timo L. M. ten Hagen, Johan Hansson, Alexander M. M. Eggermont, and for the EORTC Melanoma Group and the Nordic Melanoma Group. Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon. Journal of the National Cancer Institute, 2009; DOI: 10.1093/jnci/djp132

Cite This Page:

Journal of the National Cancer Institute. "Lack Of Association Between Autoimmune Antibodies And Improved Outcome In Melanoma Patients." ScienceDaily. ScienceDaily, 9 June 2009. <www.sciencedaily.com/releases/2009/06/090609215931.htm>.
Journal of the National Cancer Institute. (2009, June 9). Lack Of Association Between Autoimmune Antibodies And Improved Outcome In Melanoma Patients. ScienceDaily. Retrieved November 20, 2014 from www.sciencedaily.com/releases/2009/06/090609215931.htm
Journal of the National Cancer Institute. "Lack Of Association Between Autoimmune Antibodies And Improved Outcome In Melanoma Patients." ScienceDaily. www.sciencedaily.com/releases/2009/06/090609215931.htm (accessed November 20, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

UN Says It Will Scale Up Its Ebola Response

UN Says It Will Scale Up Its Ebola Response

AFP (Nov. 20, 2014) — UN Resident Coordinator David McLachlan-Karr and WHO representative in the country Daniel Kertesz updated the media on the UN Ebola response on Wednesday. Duration: 00:51 Video provided by AFP
Powered by NewsLook.com
Takata Offers "sincerest Condolences" To Victims of Malfunctioning Airbag

Takata Offers "sincerest Condolences" To Victims of Malfunctioning Airbag

Reuters - US Online Video (Nov. 20, 2014) — U.S. Congress hears from a victim and company officials as it holds a hearing on the safety of Takata airbags after reports of injuries. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Obesity Costs Almost As Much As War And Terrorism

Obesity Costs Almost As Much As War And Terrorism

Newsy (Nov. 20, 2014) — The newest estimate of the cost of obesity is pretty jarring — $2 trillion. But how did researchers get to that number? Video provided by Newsy
Powered by NewsLook.com
Ebola Crisis Affecting US Adoptions

Ebola Crisis Affecting US Adoptions

AP (Nov. 20, 2014) — The Sanborn family had hoped they'd be able to bring home their 5-year-old adopted son from Liberia by now. But Ebola has forced them to wait. The boy is just one of thousands of orphans in West Africa who've been impacted by the deadly virus. (Nov. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins